Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1No longer available 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Extranodal NK-T-Cell 1

Interventions

Cyclophosphamide 32Rituximab 24zanubrutinib 19Vincristine 16fludarabine 14Prednisone 14Magnetic Resonance Spectroscopy 14venetoclax 13blinatumomab 13Specimen Handling 13Doxorubicin 13Bendamustine Hydrochloride 11obinutuzumab 10Lenalidomide 9Dexamethasone 9polatuzumab vedotin 8Methotrexate 8Biopsy 8glofitamab 7Prednisolone 7Cytarabine 7Radiotherapy 6N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 6pirtobrutinib 5pegaspargase 5Immunotherapy, Adoptive 5tislelizumab 4tafasitamab 4selinexor 4orelabrutinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × sugemalimab × Lymphoid × Clear all
NCT05700448 2026-05-27

Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma

CStone Pharmaceuticals

Phase 3 Not yet recruiting
150 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡